

Norway

Recent and planned developments in pharmaceutical policies 2017

Special topic: hospital medicines

CHANGES IN PRICING

01/04/2017: Managed Entry Agreement for Repatha and Praluent

- Limited to 100 million NOK annual expenditure
- Clawback – percentage secret

Planned changes:

01/01/2018: More regressive pharmacy mark-up

- Pharmacy Purchasing Price 200<NOK (22 EUR); percentage mark-up reduced from 7% to 2,25%, mark-up per pack increased from 25 to 29 NOK
- Introduction of 0,5% mark-up for cooled products
- Introduction of minimum prices for stepped price (50NOK)

01/01/2018 Increase of control fee from 0.7% to 1% of PPP

- Significant reduction (50%) of fee for marketing licences in return

CHANGES IN REIMBURSEMENT

More medicines were transferred from the National Insurance Scheme to the Regional Health Authorities' budget (ca. 35% of pharmaceutical expenditures in 2018):

01/01/2017 Pulmonial Arterial Hypertension

01/05/2017 Cancer

Planned changes:

01/01/2018 All publicly financed drugs need to undergo an HTA


- NoMA is responsible for assessment
- Intended to lead to more cost-effective use of drugs – NoMA and Drug Procurement Cooperation are assessing options for faster HTA

OTHER CHANGES

- Inhalation guidance in pharmacies subsidised by government (trial period extended by 3 years)
- Hospitals (and regional health authorities) are improving their governance and pharmaceutical expense:
 - o More cost-effective treatment by switching all patients to generic or biosimilar with lowest price (exception when there is medical contraindication)
 - o CEOs of regional health authorities must support recommendations about cost-effective use
 - o Increase of staff to perform tenders in the purchasing cooperation

SPECIAL TOPIC: HOSPITAL MEDICINES

- **Pharmaceutical expenditure** (in-patient sector, PRP,):
 - o 2016: 3.3 billion NOK (ca. 350mEUR) / 2017 (est.): 5.0 billion NOK (ca. 530mEUR)
- **Procurement:** Joint procurement (Drug Procurement Cooperation) mostly through tenders; distribution by one of the three wholesalers (tender contracts)
- **Hospital prices:** list prices publicly available until 1.1.2017, now secret
- **Financing:** follows prescriber



- **HTA:**

- **Main challenges in 2017**

- o The extensive transfer of drugs to the RHA budgets made it challenging to have tenders on all transferred drugs
- o Secrecy of prices